Holen Sie sich die Stockscreener-App
9.98
37.00%
-5.93
Schlusskurs vom Vortag:
$15.91
Offen:
$11.8
24-Stunden-Volumen:
6.61M
Relative Volume:
10.56
Marktkapitalisierung:
$1.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-4.8683
EPS:
-2.05
Netto-Cashflow:
$-138.01M
1W Leistung:
-39.21%
1M Leistung:
-43.37%
6M Leistung:
-54.67%
1J Leistung:
+7.32%
1-Tages-Spanne:
$9.68
$12.24
1-Wochen-Bereich:
$9.68
$16.68
52-Wochen-Spanne:
$9.06
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| KURA | 10.06 | 1.21B | 0 | -168.09M | -138.01M | -2.05 |
| VRTX | 446.29 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.44 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.84 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Kura Oncology tumbles as Kyowa collaboration seen hitting M&A prospects By Investing.com - Investing.com Canada
Buy rating reiterated for Kura Oncology stock, analyst raises target on ziftomenib advancements - Investing.com Canada
Kura and Kyowa Kirin sign ziftomenib deal - The Pharma Letter
Kura partners with Kyowa Kirin to advance AML treatment - Pharmaceutical Technology
Earnings call: Kura Oncology reports on ziptamenib's progress in Q3 - Investing.com
Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration - MarketWatch
Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - MSN
KURAKura Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - PR Newswire
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
StockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology stock gains spotlight amid Revuforj's FDA approval By Investing.com - Investing.com UK
Objective long/short (KURA) Report - Stock Traders Daily
Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology I - GuruFocus.com
Kura Oncology (NASDAQ:KURA) Raised to “Hold” at StockNews.com - Defense World
Kura Oncology's SWOT analysis: ziftomenib drives stock potential amid AML market - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
FY2026 EPS Estimate for Kura Oncology Lifted by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $28.83 - MarketBeat
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology: Q3 Earnings Snapshot - San Francisco Chronicle
Kura Oncology Reports Third Quarter 2024 Financial Results - The Manila Times
Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
When the Price of (KURA) Talks, People Listen - Stock Traders Daily
Kura Oncology to present AML trial data at ASH meeting - Investing.com
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times
Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com
Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
UBS Group Initiates Coverage on Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan
Kura Oncology Enters Oversold Territory (KURA) - Nasdaq
Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts - MarketBeat
An analyst sees good growth prospects for Kura Oncology Inc (KURA) - SETE News
Where are the Opportunities in (KURA) - Stock Traders Daily
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):